GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Hydromorphone injection - DILAUDID / DILAUDID-HP

Read renal action and limits
Local official-label summarySource retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

DILAUDID injection / DILAUDID-HP / Dilaudid / Hydromorphone hydrochloride

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Dilaudid - product and source limitations

Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Dilaudid - product and source limitations

Official source

Dilaudid - labeled renal guidance

Renal action and limits

Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection
Renal impairment categories as defined by the cited product label

Action or finding
Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity.
Limits and monitoring
Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 6, posted Aug 31, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Dilaudid | GlobalRPh RX passage All evidence
Product / population
Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection
Renal measure
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 6, posted Aug 31, 2026
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2.4 Dosage Modifications in Patients with Renal Impairment / 5.7 Adrenal Insufficiency / 8.7 Renal Impairment

Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity. Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.

Source revision: DailyMed SPL version 6, posted Aug 31, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9eebd88a-5632-460f-b7b6-26c8a180540d

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Dilaudid - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 6, posted Aug 31, 2026

Renal measure: Renal impairment categories as defined by the cited product label

Read this dated source finding
Rxlist

Dilaudid - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Dilaudid - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection

Renal method: Renal impairment categories as defined by the cited product label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

GlobalRPh RX List - DILAUDID injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Parenteral hydromorphone; high-potency presentation requires separate product checks

Renal method: Clinical degree of renal impairment; no fixed band-to-fraction mapping
Retrieved: 2026-09-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Dilaudid - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Dilaudid - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Dilaudid - product and source limitations

Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.

How to use this: Apply only to the stated formulation, indication and renal population.

Dilaudid - labeled renal guidanceDilaudid - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDilaudid - labeled renal guidanceGlobalRPh RX List - DILAUDID injectionDilaudid - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/dilaudid-hp-drug/

Exact product and population

Parenteral hydromorphone; high-potency presentation requires separate product checks

RDM38-SCOPE-hydromorphone-injection-dilaudid · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Dilaudid - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 6, posted Aug 31, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.4 Dosage Modifications in Patients with Renal Impairment / 5.7 Adrenal Insufficiency / 8.7 Renal Impairment

Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity. Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.

RDM74-dilaudid-official-1 · Source locator: Renal guidance: 2.4 Dosage Modifications in Patients with Renal Impairment / 5.7 Adrenal Insufficiency / 8.7 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9eebd88a-5632-460f-b7b6-26c8a180540d
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 6, posted Aug 31, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
a2ee7efd6b5f5b976f0bacd9b4c531c1cfab0484a322430b2d7662308dae819d
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - DILAUDID injection

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Parenteral hydromorphone; high-potency presentation requires separate product checks

Renal method: Clinical degree of renal impairment; no fixed band-to-fraction mapping
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In renal impairment, initiate hydromorphone injection at one-quarter to one-half of the usual starting dose, depending on the degree of impairment. Titrate cautiously and monitor closely for sedation and respiratory depression. The excerpt does not assign an automatic quarter-dose or half-dose to a specific CrCl band or supply a dialysis schedule.

The high-potency presentation has additional opioid-tolerance restrictions. Confirm the exact concentration and the complete product instructions; these injection instructions are not an oral extended-release conversion rule.

RDM38-rxlist-hydromorphone-injection-dilaudid-b047ee946f-C1 · Source locator: Dosage: renal impairment; pharmacokinetics

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/dilaudid-hp-drug/
Retrieved
2026-09-07
Renal-function method
Clinical degree of renal impairment; no fixed band-to-fraction mapping
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b21823918bfe384cb7077e3554e3058d6763d1c611a8b16efac9ce816b65082b
Rxlist

Dilaudid - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity.

RDM74-dilaudid-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/dilaudid-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e2ad044330acf1c388db145964a2554796d298306988b253442f0b32c6923661

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/dilaudid-hp-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
10b570592b338c2fc3ca4740e65fe40f635502b5de59f8484f5dfd6d48037605
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top